The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
about
Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactorSerotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patientsRapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the ratF15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile5-HT(1A) receptor function in major depressive disorderSignal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonistVilazodone for the Treatment of Depression: An UpdateNeuroendocrine immunoregulation in multiple sclerosisDiabetes-associated depression: the serotonergic system as a novel multifunctional targetTranscriptional regulation of the 5-HT1A receptor: implications for mental illnessNeuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment?Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsTowards a Functional Understanding of PGO Waves.Genetic variation in cortico-amygdala serotonin function and risk for stress-related diseaseCRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorderSerotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expressionA review of vilazodone, serotonin, and major depressive disorder.Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeysExercise benefits brain function: the monoamine connectionFibroblast growth factor 8 deficiency compromises the functional response of the serotonergic system to stressSexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression.Effects of serotonin (5-HT)1A and 5-HT2A receptor agonists on schedule-controlled responding in rats: drug combination studies.Pre-gestational stress reduces the ratio of 5-HIAA to 5-HT and the expression of 5-HT1A receptor and serotonin transporter in the brain of foetal rat.Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability.Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain.Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.Striatal dopamine D2/3 receptor availability in treatment resistant depressionSystemic inflammation alters central 5-HT function as determined by pharmacological MRIAn open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depressionCerebral 5-HT2A receptor binding, but not mGluR2, is increased in tryptophan hydroxylase 2 decrease-of-function miceVilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action.Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex.5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in ratsUnderstanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and DiseaseTreating major depression with yoga: A prospective, randomized, controlled pilot trialSerotonin transporters: implications for antidepressant drug development.DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder
P2860
Q24305619-AC88D0A3-BFE7-40A2-8659-D3648E384BB9Q24554505-E9ABA8A8-6A38-4E2B-85D9-DEB81BD73AF0Q24564955-605EF0F6-E058-46C5-922D-B262E7F6707AQ24564963-FF7E2119-6BDA-422D-A554-F8983F638AF3Q24564964-9A4F3D2C-252D-4733-B1E5-39A585EE6D52Q24643511-C348D47C-1A7E-464C-9BD7-09D8291CF976Q24644854-30066C79-DD03-4C09-A6F8-23184999C40FQ26745605-C5D87F59-1E96-44F8-8A7B-8884D236D224Q26864449-1D698185-92EA-40F8-A09D-7F1BF06F5AEAQ26864574-94A2C718-185F-4A99-95F9-417FE6C959FFQ26999691-2EE48963-8761-4B10-8274-A355F26CEE3FQ27024858-E2E32B9C-81C9-4BC8-A7FB-297C0338AFEFQ28305100-E68B406A-A34C-41B8-AC99-9814C9F396B6Q30360797-3406AF36-A2EA-41E4-8DEE-CD990E559FB1Q30487278-275F4203-6E6B-42B8-8ECF-8A54D145F4B5Q30494303-B7EED369-BCE0-40BC-B921-30AD4CC4226FQ30495060-B60FFDDE-E22D-4F92-9933-09BC8B93931CQ33719240-BC51858C-2DCB-4284-B10D-68A905E58785Q33719414-2F04F599-26DE-4C64-8660-2EC29C8B2FDCQ33721197-278508E8-A9C3-444F-B09D-A17BFFEB5165Q33755211-C6C336EB-8281-4BE6-84BC-263F8CA46D36Q33772106-7F07FBDA-E7FE-44CC-80CD-764036DE9E74Q33845696-8596CC88-B182-48B9-A74E-6075B3753B48Q33961770-FB3EFDBD-0E81-470D-9650-876B1544CDA4Q34087082-34C96499-C19C-44E4-8AFD-EC098726D319Q34175768-9DDBD3DB-5857-4D74-B52A-4B0BFDE33D23Q34253463-2F80D074-F1A0-4F54-958E-FD51ECE4916EQ34293216-B50FF8FE-D03F-4BDF-952D-87AD89897F45Q34396223-DEA0EC96-5BD1-4F05-BD70-53DF11A74178Q34550088-1B8E87B7-35DF-4300-BF18-70E2966C6C29Q34615371-C8E25A7E-2D5D-44A1-B048-972C6B7E1D8EQ34642676-288927A3-ADA5-4D2D-8B1E-0A33073853B6Q35068582-758962EF-0062-4A3C-B3C0-50155A2508D8Q35330385-26D3A0D4-8300-4E96-AEAA-6F8C2F1EAF63Q36126606-742A09F4-97AF-4BA5-ADB6-217B90A1D11CQ36266782-36817A26-CBB5-4578-B399-B5FAC215E26FQ36300230-32CD43E3-C465-440B-8CDE-84FA9DFBD282Q36310727-C41E3513-D0A6-4FB7-950B-54C748F0080EQ36341615-2DCA1DCB-8A28-4C21-BAB0-58C5787025B2Q36485741-E00501AC-D02D-4C56-B220-70FE24C27794
P2860
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@ast
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@en
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@nl
type
label
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@ast
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@en
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@nl
prefLabel
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@ast
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@en
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@nl
P2093
P2860
P1476
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
@en
P2093
Albert Adell
Francesc Artigas
Mercè Amargós-Bosch
Pau Celada
P2860
P304
P577
2004-07-01T00:00:00Z